《Disney +》 迪士尼、Marvel、彼思、星球大戰…  Nintendo Switch版LEGO Marvel Super Heroes 12月16日發售!   完整再現肉感大腿…!萊莎2與DOAXVV聯動!「ライザコーデガチャ・2021」活動開跑!!   「寶可夢 晶燦鑽石・明亮珍珠」FINAL PV & 新情報公開!   失落的龍絆2.5周年紀念!納姆頻道公布眾多活動情報!   《決勝時刻:先鋒》將於11月5日上市   原神2.1版本更新:在提瓦特世界和亞蘿伊一起狩獵吧!   《Street Fighter V》春季更新帶來仙人Oro與使用靈魂力量的Rose等角色情報   在全新的《Sackboy: A Big Adventure》針織競速破關挑戰中試試自己的技能和反應能力 

Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients


BARCELONA, Jul 28, 2023 - (亞太商訊) - Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has received full study approval for its new Phase 1b clinical trial, which will evaluate the combination of the first-in-class MYC inhibitor, OMO103, together with the standard of care (SoC) regimen Gemcitabine and Nab-Paclitaxel in metastatic Pancreatic Ductal Adenocarcinoma (PDAC) patients in first line. PDAC is the most common form of pancreatic cancer. Currently, it is the fourth highest cause of cancer mortality worldwide and its incidence is rising steeply. Current therapies offer limited chance of a lasting cure and the five-year survival rate is one of the lowest among the most commonly occurring cancers.

MYC is an oncoprotein deregulated in most -if not all- types of cancers. It is activated in many PDAC cases, where it contributes to aggressiveness of the disease and resistance to treatments. The company recently completed a FIH Phase 1 study of OMO103 in all-comers solid tumor patients, demonstrating excellent safety and promising anti-tumor activity.

Manuela Niewel, MD, PhD, Chief Medical Officer of the company, leading Peptomyc's clinical development, regulatory and medical affairs activities, says: "I am excited to be able to start our new Phase 1b study in PDAC patients. With OMO-103, we hope to address this devastating disease and one of the highest unmet medical needs in the oncology field".

This Phase 1b combination study will be conducted in four sites in Spain. The lead PI will be Dr. Teresa Macarulla at the Vall d'Hebron Institute of Oncology in Barcelona, and she will collaborate with Dr. Andres Munoz at the Hospital Gregorio Maranon in Madrid, Dr. Mariona Calvo at the ICO-Hospitalet in Barcelona, and Dr. Roberto Pazo at the Hospital Miguel Servet in Zaragoza. The study is planned to start in Q3/2023.

About Peptomyc

Peptomyc (www.peptomyc.com) is a spin-off from VHIO - the Vall d'Hebron Institute of Oncology - and ICREA - the Catalan Institute of Research and Advanced Studies - founded in December 2014 in Barcelona, Spain. The company is focused on the development of innovative cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment and based on Dr. Soucek's scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years. It is the first company to have successfully completed a Phase I clinical trial with a direct MYC inhibitor.

Contact Information
Laura Soucek
[email protected]

Copyright 2023 亞太商訊. All rights reserved. www.acnnewswire.com
ACN Newswire